Cargando…

The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective

BACKGROUND: Atrial fibrillation (AF) imposes a substantial clinical and economic burden on the U.S. health care system. Despite national guidelines that recommend oral anticoagulation for stroke prevention, the literature consistently reports its underuse in AF patients with moderate to high stroke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casciano, Julian P., Dotiwala, Zenobia J., Martin, Bradley C., Kwong, Winghan Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437466/ https://www.ncbi.nlm.nih.gov/pubmed/23627576 http://dx.doi.org/10.18553/jmcp.2013.19.4.302

Ejemplares similares

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Impact of Atrial Fibrillation on Stroke‐Related Healthcare Costs
por: Sussman, Matthew, et al.
Publicado: (2013)

Cost Reduction Behaviors and Cost-Related Medication Nonadherence in Older Adults with Atrial Fibrillation
por: Bamgbade, Benita, et al.
Publicado: (2021)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
por: Björholt, Ingela, et al.
Publicado: (2007)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis
por: AbuDagga, Azza, et al.
Publicado: (2014)

Prevalence and Predictors of Nonadherence to Direct Oral Anticoagulant Treatment in Patients with Atrial Fibrillation
por: van der Horst, Sabine F. B., et al.
Publicado: (2023)

Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
por: Dunn, Keith, et al.
Publicado: (2018)

Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
por: Reddy, Vivek Y., et al.
Publicado: (2016)

Value of peripheral blood eosinophil markers to predict severity of asthma
por: Casciano, Julian, et al.
Publicado: (2016)

Burden of asthma with elevated blood eosinophil levels
por: Casciano, Julian, et al.
Publicado: (2016)

Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy
por: Stephenson, Judith J, et al.
Publicado: (2018)

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
por: Sorensen, Sonja V., et al.
Publicado: (2013)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Review of the cost of venous thromboembolism
por: Fernandez, Maria M, et al.
Publicado: (2015)

Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018
por: Li, Meng, et al.
Publicado: (2021)

Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
por: Rossiter, Louis F, et al.
Publicado: (2020)

Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
por: Mendoza-Sanchez, Jose, et al.
Publicado: (2018)

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
por: Jaberi, Neda, et al.
Publicado: (2021)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Characteristics of warfarin under-prescription in older adults with atrial fibrillation
por: Rashid, Sana, et al.
Publicado: (2021)

A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation
por: Wirbka, Lucas, et al.
Publicado: (2022)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
por: Kee, Youn Kyung, et al.
Publicado: (2023)

Cost-related underuse of medications in older adults: ELSI-Brazil
por: de Loyola, Antônio Ignácio, et al.
Publicado: (2018)

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
por: You, Joyce H. S., et al.
Publicado: (2012)

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis
por: Shiffman, Dov, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1sdst9jelv8pl7mpngafm00g1c